REFERENCES
ACCP Abstract Booklet. (2021). Clinical Pharmacology in Drug Development, 10 (S1), 1-104. doi:https://doi.org/10.1002/cpdd.1004
Avedissian, S. N., Pais, G. M., Liu, J., Rhodes, N. J., & Scheetz, M. H. (2019). Piperacillin-Tazobactam Added to Vancomycin Increases Risk for AKI: Fact or Fiction? Clin Infect Dis doi:10.1093/cid/ciz1189
Avedissian, S. N., Pais, G. M., O’Donnell, J. N., Lodise, T. P., Liu, J., Prozialeck, W. C., … Scheetz, M. H. (2019). Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. J Antimicrob Chemother, 74 (8), 2326-2334. doi:10.1093/jac/dkz167
Baggs, J., Fridkin, S. K., Pollack, L. A., Srinivasan, A., & Jernigan, J. A. (2016). Estimating National Trends in Inpatient Antibiotic Use Among US Hospitals From 2006 to 2012. JAMA Intern Med, 176 (11), 1639-1648. doi:10.1001/jamainternmed.2016.5651
Becerir, T., Tokgün, O., & Yuksel, S. (2021). The therapeutic effect of Cilastatin on drug-induced nephrotoxicity: a new perspective. Eur Rev Med Pharmacol Sci, 25 (17), 5436-5447. doi:10.26355/eurrev_202109_26651
Chang, J., Pais, G. M., Valdez, K., Marianski, S., Barreto, E. F., & Scheetz, M. H. (2022). Glomerular Function and Urinary Biomarker Changes between Vancomycin and Vancomycin plus Piperacillin-Tazobactam in a Translational Rat Model. Antimicrob Agents Chemother, 66 (3), e0213221. doi:10.1128/aac.02132-21
Christensen, E. I., Nielsen, S., Moestrup, S. K., Borre, C., Maunsbach, A. B., de Heer, E., … Verroust, P. (1995). Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol, 66 (4), 349-364.
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., … Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br J Pharmacol, 175 (7), 987-993. doi:10.1111/bph.14153
Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). . (2005). In.
H. Wickham. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2016.
Hakeam, H. A., AlAnazi, L., Mansour, R., AlFudail, S., & AlMarzouq, F. (2019). Does nephrotoxicity develop less frequently when vancomycin is combined with imipenem-cilastatin than with meropenem? A comparative study. Infect Dis (Lond), 51 (8), 578-584. doi:10.1080/23744235.2019.1619934
He, M., Souza, E., Matvekas, A., Crass, R. L., & Pai, M. P. (2021). Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model. Antimicrob Agents Chemother, 65 (4)doi:10.1128/AAC.02141-20
Hori, Y., Aoki, N., Kuwahara, S., Hosojima, M., Kaseda, R., Goto, S., … Saito, A. (2017). Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity. J Am Soc Nephrol, 28 (6), 1783-1791. doi:10.1681/ASN.2016060606
Humanes, B., Jado, J. C., Camano, S., Lopez-Parra, V., Torres, A. M., Alvarez-Sala, L. A., … Lazaro, A. (2015). Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity. Biomed Res Int, 2015 , 704382. doi:10.1155/2015/704382
Im, D. S., Shin, H. J., Yang, K. J., Jung, S. Y., Song, H. Y., Hwang, H. S., & Gil, H. W. (2017). Cilastatin attenuates vancomycin-induced nephrotoxicity via P-glycoprotein. Toxicol Lett, 277 , 9-17. doi:10.1016/j.toxlet.2017.05.023
Kahan, F. M., Kropp, H., Sundelof, J. G., & Birnbaum, J. (1983). Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother, 12 Suppl D , 1-35. doi:10.1093/jac/12.suppl_d.1
Kusama, M., Yamamoto, K., Yamada, H., Kotaki, H., Sato, H., & Iga, T. (1998). Effect of cilastatin on renal handling of vancomycin in rats.J Pharm Sci, 87 (9), 1173-1176. doi:10.1021/js9801135
Kuwahara, S., Hosojima, M., Kaneko, R., Aoki, H., Nakano, D., Sasagawa, T., … Saito, A. (2016). Megalin-Mediated Tubuloglomerular Alterations in High-Fat Diet-Induced Kidney Disease. J Am Soc Nephrol, 27 (7), 1996-2008. doi:10.1681/ASN.2015020190
Legg, A., Meagher, N., Johnson, S. A., Roberts, M. A., Cass, A., Scheetz, M. H., … Tong, S. Y. C. (2022). Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial. Clin Drug Investig doi:10.1007/s40261-022-01204-z
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., … Chambers, H. F. (2011). Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis, 52 (3), e18-55. doi:10.1093/cid/ciq146
Liu, J., Tong, S. Y. C., Davis, J. S., Rhodes, N. J., Scheetz, M. H., & Group, C. S. (2020). Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study. Open Forum Infect Dis, 7 (12), ofaa538. doi:10.1093/ofid/ofaa538
Lodise, T. P., Rosenkranz, S. L., Finnemeyer, M., Evans, S., Sims, M., Zervos, M. J., … Holland, T. L. (2020). The Emperor’s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clin Infect Dis, 70 (8), 1536-1545. doi:10.1093/cid/ciz460
Moestrup, S. K., Cui, S., Vorum, H., Bregengård, C., Bjørn, S. E., Norris, K., … Christensen, E. I. (1995). Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest, 96 (3), 1404-1413. doi:10.1172/jci118176
Nakamura, T., Kokuryo, T., Hashimoto, Y., & Inui, K. I. (1999). Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats. J Pharm Pharmacol, 51 (2), 227-232. doi:10.1211/0022357991772187
National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US); 2011. Available from: https://www.ncbi.nlm.nih.gov/books/NBK54050/ doi: 10.17226/12910. In.
Pais, G. M., Avedissian, S. N., O’Donnell, J. N., Rhodes, N. J., Lodise, T. P., Prozialeck, W. C., … Scheetz, M. H. (2019). Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury. Antimicrob Agents Chemother, 63 (7), e00079-00019. doi:10.1128/AAC.00079-19
Pais, G. M., Chang, J., Liu, J., & Scheetz, M. H. (2022). A translational rat model to assess glomerular function changes with vancomycin. Int J Antimicrob Agents, 59 (5), 106583. doi:10.1016/j.ijantimicag.2022.106583
Pais, G. M., Liu, J., Avedissian, S. N., Hiner, D., Xanthos, T., Chalkias, A., … Scheetz, M. H. (2020). Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. J Antimicrob Chemother, 75 (5), 1228-1236. doi:10.1093/jac/dkz563
Pais, G. M., Liu, J., Zepcan, S., Avedissian, S. N., Rhodes, N. J., Downes, K. J., … Scheetz, M. H. (2020). Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention.Pharmacotherapy, 40 (5), 438-454. doi:10.1002/phar.2388
Primaxin Package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf. Merck 12/2016. In.
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., … Lomaestro, B. M. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm, 77 (11), 835-864. doi:10.1093/ajhp/zxaa036
Scheetz, M. H., Pais, G. M., Lodise, T. P., Tong, S. Y. C., Davis, J. S., O’Donnell, J. N., … Avedissian, S. N. (2021). Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships. Antimicrob Agents Chemother, 65 (10), e0106021. doi:10.1128/aac.01060-21
Suzuki, T., Yamaguchi, H., Ogura, J., Kobayashi, M., Yamada, T., & Iseki, K. (2013). Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother, 57 (12), 6319-6324. doi:10.1128/aac.00254-13
Tong, S. Y. C., Lye, D. C., Yahav, D., Sud, A., Robinson, J. O., Nelson, J., … Davis, J. S. (2020). Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. Jama, 323 (6), 527-537. doi:10.1001/jama.2020.0103
Toyoguchi, T., Takahashi, S., Hosoya, J., Nakagawa, Y., & Watanabe, H. (1997). Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrob Agents Chemother, 41 (9), 1985-1990. doi:10.1128/AAC.41.9.1985
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013). Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother, 57 (2), 734-744. doi:10.1128/AAC.01568-12
Wunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., Kunkel, M. J., Baruch, A., … Chastre, J. (2012). Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis, 54 (5), 621-629. doi:10.1093/cid/cir895